PL2895600T3 - Peptydy UBE2T i szczepionki je zawierające - Google Patents

Peptydy UBE2T i szczepionki je zawierające

Info

Publication number
PL2895600T3
PL2895600T3 PL13837757T PL13837757T PL2895600T3 PL 2895600 T3 PL2895600 T3 PL 2895600T3 PL 13837757 T PL13837757 T PL 13837757T PL 13837757 T PL13837757 T PL 13837757T PL 2895600 T3 PL2895600 T3 PL 2895600T3
Authority
PL
Poland
Prior art keywords
same
vaccines containing
ube2t
peptides
ube2t peptides
Prior art date
Application number
PL13837757T
Other languages
English (en)
Polish (pl)
Inventor
Takuya Tsunoda
Ryuji Osawa
Sachiko Yoshimura
Tomohisa Watanabe
Original Assignee
Oncotherapy Science, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncotherapy Science, Inc. filed Critical Oncotherapy Science, Inc.
Publication of PL2895600T3 publication Critical patent/PL2895600T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14Blood; Artificial blood
    • A61K35/17Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • A61K39/001154Enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0634Cells from the blood or the immune system
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0634Cells from the blood or the immune system
    • C12N5/0636T lymphocytes
    • C12N5/0638Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/93Ligases (6)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y603/00Ligases forming carbon-nitrogen bonds (6.3)
    • C12Y603/02Acid—amino-acid ligases (peptide synthases)(6.3.2)
    • C12Y603/02019Ubiquitin-protein ligase (6.3.2.19), i.e. ubiquitin-conjugating enzyme
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515Animal cells
    • A61K2039/5154Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50Cell markers; Cell surface determinants
    • C12N2501/515CD3, T-cell receptor complex
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70Enzymes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00Coculture with; Conditioned medium produced by
    • C12N2502/11Coculture with; Conditioned medium produced by blood or immune system cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00Coculture with; Conditioned medium produced by
    • C12N2502/11Coculture with; Conditioned medium produced by blood or immune system cells
    • C12N2502/1114T cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
PL13837757T 2012-09-11 2013-09-09 Peptydy UBE2T i szczepionki je zawierające PL2895600T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261699550P 2012-09-11 2012-09-11
PCT/JP2013/005321 WO2014041784A1 (en) 2012-09-11 2013-09-09 Ube2t peptides and vaccines containing the same
EP13837757.7A EP2895600B1 (en) 2012-09-11 2013-09-09 Ube2t peptides and vaccines containing the same

Publications (1)

Publication Number Publication Date
PL2895600T3 true PL2895600T3 (pl) 2020-10-05

Family

ID=50277926

Family Applications (1)

Application Number Title Priority Date Filing Date
PL13837757T PL2895600T3 (pl) 2012-09-11 2013-09-09 Peptydy UBE2T i szczepionki je zawierające

Country Status (17)

Country Link
US (2) US10092634B2 (enExample)
EP (1) EP2895600B1 (enExample)
JP (1) JP6283861B2 (enExample)
KR (1) KR102110873B1 (enExample)
CN (2) CN107881158B (enExample)
AU (1) AU2013317194B2 (enExample)
BR (1) BR112015004349B1 (enExample)
CA (1) CA2873155C (enExample)
DK (1) DK2895600T3 (enExample)
ES (1) ES2784862T3 (enExample)
IL (1) IL236690B (enExample)
MX (1) MX362912B (enExample)
PL (1) PL2895600T3 (enExample)
RU (1) RU2663350C2 (enExample)
SG (2) SG11201501761SA (enExample)
TW (1) TWI632162B (enExample)
WO (1) WO2014041784A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7572700B2 (ja) 2015-10-19 2024-10-24 ユニバーシティ オブ メリーランド ボルチモア 改変ヒト初代血液樹状細胞株を生成するための方法
JP6715004B2 (ja) 2015-12-25 2020-07-01 宏 半田 免疫賦活化剤およびその製造方法
MX2019008878A (es) 2017-01-25 2020-02-13 Ose Immunotherapeutics Metodo para fabricar una emulsion estable para suministro de peptidos.
US11598780B2 (en) * 2017-10-06 2023-03-07 The University Of Chicago Engineering lymphocytes with specific alpha and beta chains on their t-cell receptor
KR102322832B1 (ko) * 2019-04-22 2021-11-12 한국과학기술연구원 인간 백혈구 항원 a24:02 대립유전자에 특이적으로 결합하는 펩타이드 및 이의 용도
CN113679829B (zh) 2020-05-18 2024-01-02 北京繁易纳维科技有限公司 一种预防癌症术后复发的肿瘤疫苗及其制备方法和应用

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5804566A (en) 1993-08-26 1998-09-08 The Regents Of The University Of California Methods and devices for immunizing a host through administration of naked polynucleotides with encode allergenic peptides
US5679647A (en) 1993-08-26 1997-10-21 The Regents Of The University Of California Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides
US5739118A (en) 1994-04-01 1998-04-14 Apollon, Inc. Compositions and methods for delivery of genetic material
US5736524A (en) 1994-11-14 1998-04-07 Merck & Co.,. Inc. Polynucleotide tuberculosis vaccine
US5922687A (en) 1995-05-04 1999-07-13 Board Of Trustees Of The Leland Stanford Junior University Intracellular delivery of nucleic acids using pressure
WO1998004720A1 (en) 1996-07-26 1998-02-05 Sloan-Kettering Institute For Cancer Research Method and reagents for genetic immunization
WO1999067288A1 (en) 1998-06-25 1999-12-29 Sumitomo Pharmaceuticals Company, Limited Tumor antigen peptides originating in cyclophilin b
JP2002520054A (ja) 1998-07-14 2002-07-09 コリクサ コーポレイション 前立腺癌の治療及び診断のための組成物及び方法
CA2345817C (en) 1998-10-05 2013-02-12 M&E Biotech A/S Novel methods for therapeutic vaccination
US6468546B1 (en) * 1998-12-17 2002-10-22 Corixa Corporation Compositions and methods for therapy and diagnosis of ovarian cancer
ATE389668T1 (de) * 2000-07-31 2008-04-15 Greenpeptide Co Ltd Tumorantigen
JP4579246B2 (ja) 2003-09-24 2010-11-10 オンコセラピー・サイエンス株式会社 乳癌を診断する方法
US20070202109A1 (en) 2003-09-24 2007-08-30 Oncotherapy Science, Inc. Method Of Diagnosing Breast Cancer
WO2008102906A1 (en) 2007-02-20 2008-08-28 Oncotherapy Science, Inc. Hspc-hrpc transition genes
TWI615403B (zh) 2007-02-21 2018-02-21 腫瘤療法 科學股份有限公司 表現腫瘤相關抗原之癌症的胜肽疫苗
TW200908998A (en) 2007-06-27 2009-03-01 Oncotherapy Science Inc Compositions and methods of treating cancer
WO2010032696A1 (ja) * 2008-09-18 2010-03-25 学校法人慶應義塾 がんの診断方法と治療方法
TWI500932B (zh) 2008-12-05 2015-09-21 Oncotherapy Science Inc Wdrpuh抗原決定位胜肽以及含此胜肽之疫苗
KR20110117112A (ko) 2008-12-24 2011-10-26 온코세라피 사이언스 가부시키가이샤 C1orf59 펩티드 및 이를 포함하는 백신
TW201102081A (en) * 2009-05-11 2011-01-16 Oncotherapy Science Inc TTK peptides and vaccines including the same
TW201216982A (en) 2010-10-21 2012-05-01 Oncotherapy Science Inc WDHD1 peptides and vaccines including the same
BR112013009276A2 (pt) 2010-10-21 2019-09-24 Oncotherapy Science Inc peptídeos de c18orf54 e vacinas incluindo os mesmos
WO2012073459A1 (en) 2010-12-02 2012-06-07 Oncotherapy Science, Inc. Tomm34 peptides and vaccines including the same

Also Published As

Publication number Publication date
MX362912B (es) 2019-02-22
RU2015113436A (ru) 2016-11-10
IL236690B (en) 2021-03-25
IL236690A0 (en) 2015-02-26
MX2015003017A (es) 2015-06-10
US20180360938A1 (en) 2018-12-20
SG10201701866QA (en) 2017-04-27
EP2895600A1 (en) 2015-07-22
CN104619833B (zh) 2018-01-02
US10092634B2 (en) 2018-10-09
US11266729B2 (en) 2022-03-08
EP2895600B1 (en) 2020-02-19
BR112015004349B1 (pt) 2022-11-01
TWI632162B (zh) 2018-08-11
US20150174223A1 (en) 2015-06-25
CN104619833A (zh) 2015-05-13
AU2013317194A1 (en) 2015-02-05
KR102110873B1 (ko) 2020-05-14
RU2663350C2 (ru) 2018-08-03
SG11201501761SA (en) 2015-04-29
CN107881158B (zh) 2021-11-16
CA2873155C (en) 2022-07-26
JP2015529219A (ja) 2015-10-05
DK2895600T3 (da) 2020-04-27
AU2013317194B2 (en) 2018-07-12
BR112015004349A2 (pt) 2017-08-08
CA2873155A1 (en) 2014-03-20
CN107881158A (zh) 2018-04-06
HK1212730A1 (en) 2016-06-17
JP6283861B2 (ja) 2018-02-28
TW201414752A (zh) 2014-04-16
WO2014041784A1 (en) 2014-03-20
EP2895600A4 (en) 2016-05-04
KR20150054710A (ko) 2015-05-20
ES2784862T3 (es) 2020-10-01

Similar Documents

Publication Publication Date Title
IL283139A (en) Proline-locked clamped peptides and their uses
SG11201500111VA (en) Peptides and uses thereof
ZA201505966B (en) Peptides and compositions
SG10201701828WA (en) Peptides and their uses
PT2855506T (pt) Péptido e utilização do mesmo
SG10201707316WA (en) Kntc2 peptides and vaccines containing the same
IL245924A0 (en) topk peptides and components comprising them
EP2825548A4 (en) MODIFIED KISSPEPTIN PEPTIDES AND USES THEREOF
IL236690A0 (en) ube2t peptides and components containing them
IL228995A0 (en) b5sema peptides and components containing them
EP2872530A4 (en) KIF20A EPITOPE PEPTIDES FOR TH1 CELLS AND VACCINES CONTAINING SAME
PL2809342T3 (pl) Peptyd dwufunkcyjny
EP3049153B8 (de) Zyklische, amyloid-beta-bindende peptide und deren verwendung
EP2872531A4 (en) LY6K EPITOPE PEPTIDES FOR TH1 CELLS AND VACCINES CONTAINING SAME
ZA201303886B (en) Tomm34 peptides and vaccines including the same
IL221474A0 (en) Hjurp peptides and vaccines including the same
ZA201504462B (en) TGFß-DERIVED POLYPEPTIDES AND USES THEREOF
IL237400A0 (en) Rhizobacteria and its uses
ZA201207342B (en) Ect2 peptides and vaccines including the same
IL238788A0 (en) sema5b peptides and components containing them
IL225552A0 (en) wdhd1 peptides and vaccines containing them
IL225553A0 (en) 54orf18c peptides and vaccines containing them
EP2873676A4 (en) PEPTIDE WITH LOW MOLECULAR WEIGHT AND USE THEREOF
GB201214769D0 (en) Methodsa and peptides
IL215915A0 (en) Ttk peptides and vaccines including the same